Origin and immunoescape of uterine cervical cancer

Dorien Van Hede; Inge Langers; Philippe Delvenne; Nathalie Jacobs

doi:10.1016/j.lpm.2014.09.005

Origin and immunoescape of uterine cervical cancer

Presse Med. 2014 Dec;43(12 Pt 2):e413-21. doi: 10.1016/j.lpm.2014.09.005. Epub 2014 Nov 4.

Authors

Dorien Van Hede¹, Inge Langers¹, Philippe Delvenne², Nathalie Jacobs³

Affiliations

¹ University of Liège, cellular and molecular immunology, GIGA-Research, 4000 Liège, Belgium.
² University of Liège, experimental pathology, GIGA-Research, 4000 Liège, Belgium.
³ University of Liège, cellular and molecular immunology, GIGA-Research, 4000 Liège, Belgium. Electronic address: n.jacobs@ulg.ac.be.

PMID: 25448124
DOI: 10.1016/j.lpm.2014.09.005

Abstract

Human papillomavirus associated uterine cervical cancer is an important public health problem since it is classified as the fourth most common cancer in women worldwide with more than 500,000 recorded cases. This review is focused on where and why HPV infection induces cervical cancers and how this virus avoids the host immune response. Immunological therapeutic approaches are also addressed.

Publication types

Review

MeSH terms

Cancer Vaccines / therapeutic use
Female
Humans
Immunotherapy / methods
Immunotherapy / trends
Mucociliary Clearance / physiology
Papillomaviridae* / immunology
Papillomaviridae* / pathogenicity
Papillomaviridae* / physiology
Papillomavirus Infections / complications
Papillomavirus Infections / immunology
Papillomavirus Vaccines / therapeutic use
Tumor Escape / physiology*
Uterine Cervical Dysplasia / immunology*
Uterine Cervical Dysplasia / therapy
Uterine Cervical Dysplasia / virology*
Uterine Cervical Neoplasms / immunology*
Uterine Cervical Neoplasms / therapy
Uterine Cervical Neoplasms / virology*

Substances

Cancer Vaccines
Papillomavirus Vaccines